Panacea Biotec Limited
Incorporated in 1984, Panacea Biotec Ltd is a research-based biotechnology company
What Panacea files
- Others80
- Important35
- Board Meeting11
- Updates9
- New Orders8
- Results1
Panacea Biotec Limited has informed the Exchange about General Updates - Book closure for the purpose of AGM
Panacea Biotec Limited has informed the Exchange about General Updates - Confirmation on letter being sent to the concerned shareholders providing the weblink for accessing the Annual Report for financial year 2025-26 and the Notice of the ensuing AGM, to be held on September 29, 2026, through Video Conferencing /...
Panacea Biotec Limited has informed the Exchange regarding a press release dated Jun 08, 2026, titled "Launch of the DENSTAR project: advancing the licensure of a tetravalent liveattenuateddengue vaccine (DengiAll®) in sub-Saharan Africa and to facilitate its global access".
Panacea Biotec's subsidiary, PBPL, announced the appointment of Krishan Kumar Jalan as an independent director and the re-appointment of Manjula Upadhyay. These moves enhance the subsidiary's board governance and bring experienced professionals to its leadership.
Panacea Biotec completed enrollment for its DengiAll® Phase III clinical trial with 10,335 participants. This pivotal step advances India's first indigenous single-shot dengue vaccine, expected to enter markets by 2027 after two years of efficacy monitoring.